The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study
Open accessAbstract
AIM: Chemotherapy side effects are often reported in clinical trials; however, there is little evidence about their incidence in routine clinical care. The objective of this study was to describe the frequency and severity of patient-reported chemotherapy side effects in routine care across treatment centres in Australia. METHODS: We conducted a prospective cohort study of individuals with breast, lung or colorectal cancer undergoing chemotherapy. Side effects were identified by patient self-report. The frequency, prevalence and incidence rates of side effects were calculated by cancer type and grade, and cumulative incidence curves for each side effect computed. Frequencies of side effects were compared between demographic subgroups using chi-squared statistics. RESULTS: Side effect data were available for 449 eligible individuals, who had a median follow-up of 5.64 months. 86% of participants reported at least one side effect during the study period and 27% reported a grade IV side effect, most commonly fatigue or dyspnoea. Fatigue was the most common side effect overall (85%), followed by diarrhoea (74%) and constipation (74%). Prevalence and incidence rates were similar across side effects and cancer types. Age was the only demographic factor associated with the incidence of side effects, with older people less likely to report side effects. CONCLUSION: This research has produced the first Australian estimates of self-reported incidence of chemotherapy side effects in routine clinical care. Chemotherapy side effects in routine care are common, continue throughout chemotherapy and can be serious. This work confirms the importance of observational data in providing clinical practice-relevant information to decision-makers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., Mendoza, T. R., Hay, J., Atkinson, T. M., Abernethy, A. P., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju244 · Cited by 1,151
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,049
On the receiving end—patient perception of the side-effects of cancer chemotherapy
Coates, A., Abraham, S., Kaye, S. B., Sowerbutts, T., Frewin, C., Fox, R. M., & Tattersall, M. H. N. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90418-2 · Cited by 997
Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer
Bonadonna, G., & Valagussa, P. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101013040103 · Cited by 774
Garrison, L. P., Neumann, P. J., Erickson, P., Marshall, D., & Mullins, C. D. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00186.x · Cited by 700
Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301801 · Cited by 577
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
(1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310226 · Cited by 556
Fromme, E. K., Eilers, K. M., Mori, M., Hsieh, Y.-C., & Beer, T. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.025 · Cited by 555
Di Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9334 · Cited by 497
Bloechl-Daum, B., Deuson, R. R., Mavros, P., Hansen, M., & Herrstedt, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6382 · Cited by 497
Changing patient perceptions of the side effects of cancer chemotherapy
Carelle, N., Piotto, E., Bellanger, A., Germanaud, J., Thuillier, A., & Khayat, D. (2002) · Cancer · doi:10.1002/cncr.10630 · Cited by 454
Henry, D. H., Viswanathan, H. N., Elkin, E. P., Traina, S., Wade, S., & Cella, D. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-007-0380-2 · Cited by 384
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
de Boer-Dennert, M., de Wit, R., Schmitz, P., Djontono, J., v Beurden, V, Stoter, G., & Verweij, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.507 · Cited by 378
Long-term toxic effects of adjuvant chemotherapy in breast cancer
Azim, H. A., de Azambuja, E., Colozza, M., Bines, J., & Piccart, M. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq683 · Cited by 292
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.306 · Cited by 287
Fatigue and Fatigability in Older Adults
Eldadah, B. A. (2010) · PM&R · doi:10.1016/j.pmrj.2010.03.022 · Cited by 262
Du, X. L., Osborne, C., & Goodwin, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.088 · Cited by 238
Bent, S., Padula, A., & Avins, A. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00007 · Cited by 177
Gallagher, P., & O’Mahony, D. (2009) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.09.001 · Cited by 163
Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer
Kahn, K. L. (2010) · JAMA · doi:10.1001/jama.2010.272 · Cited by 161
Ihbe‐Heffinger, A., EHLKEN, B., Bernard, R., Berger, K., Peschel, C., Eichler, H., Deuson, R. R., Thödtmann, J., & Lordick, F. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh110 · Cited by 138
Adverse Event Reporting in Publications Compared With Sponsor Database for Cancer Clinical Trials
Scharf, O., & Colevas, A. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3959 · Cited by 111
Wisnivesky, J. P., Smith, C., Packer, S. H., Strauss, G. M., Lurslurchachai, L., Federman, A. D., & Halm, E. A. (2011) · BMJ · doi:10.1136/bmj.d4013 · Cited by 107
Sanoff, H. K., Carpenter, W. R., Freburger, J. K., Li, L., Chen, K., Zullig, L. L., Goldberg, R. M., Schymura, M. J., & Schrag, D. (2012) · Cancer · doi:10.1002/cncr.27422 · Cited by 63
Experimental versus Observational Data in the Economic Evaluation of Pharmaceuticals
Drummond, M. (1998) · Medical Decision Making · doi:10.1177/0272989x98018002s03 · Cited by 39
Can administrative data be used to measure chemotherapy side effects?
Pearce, A. M., Haas, M. R., Viney, R. C., Haywood, P., Pearson, S., Gool, K. V., Srasuebkul, P., & Ward, R. L. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2015.990888 · Cited by 4
Self-citation
Cited by
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
Snijders, R., Brom, L., Theunissen, M., & van den Beuken-van Everdingen, M. (2023) · Cancers · doi:10.3390/cancers15030591 · Cited by 445
Prevalence and risk factors of cancer-related fatigue: A systematic review and meta-analysis
Ma, Y., He, B., Jiang, M., Yang, Y., Wang, C., Huang, C., & Han, L. (2020) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2020.103707 · Cited by 326
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Zanotelli, M. R., Rahman-Zaman, A., VanderBurgh, J. A., Taufalele, P. V., Jain, A., Erickson, D., Bordeleau, F., & Reinhart-King, C. A. (2019) · Nature Communications · doi:10.1038/s41467-019-12155-z · Cited by 165
Metadata
- Authors
- Pearce, A., Haas, M., Viney, R., Pearson, S.-A., Haywood, P., Brown, C., & Ward, R.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-10-10
- Volume
- 12
- Issue
- 10
- Pages
- e0184360
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2762997972
- Cited by
- 534
- References
- 29
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.